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We determined the rate and risk factors for end-stage renal
disease (ESRD) in consecutive patients discharged after a
cardiac event in a large, unbiased Canadian cohort that
receives universal health coverage. A total of 8236 adults
hospitalized over a 2 year period were followed for up to
7.5 years and the incidence of ESRD and mortality
determined. Of these, 113 reached ESRD (stage 5). Patients
with moderate (stage 3) and severe (stage 4) renal
insufficiency were more likely to develop ESRD than those
patients at stage 1 or 2. However, patients with moderate
renal insufficiency were 78.6 times more likely to die than to
develop ESRD. Absolute rates of progression to ESRD per
100-patient years were 0.08 at stages 1 and 2, 0.17 at stage
3 and 4.27 at stage 4. Age, diabetes, hypertension and
congestive heart failure also predicted ESRD. We found
that patients with stage 4 disease are at high risk of ESRD
after a cardiac admission while those at stage 3 are far
more likely to die than to develop ESRD.
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Kidney disease and cardiovascular disease are closely linked.
Patients with chronic renal insufficiency (CRI) have a high
burden of cardiovascular disease, and in many studies CRI is
an independent risk factor for cardiovascular disease.1 In
addition to being a risk factor for atherosclerosis, CRI is a
predictor of increased mortality in patients with congestive
heart failure (CHF) and CRI is associated with CHF.2,3
Several studies have shown that CRI is prevalent in
patients admitted for ischemic heart disease and CHF.4–9 The
subsequent risk of end-stage renal disease (ESRD) in these
patients has not been studied extensively. In a retrospective
study of Medicare patients in Georgia, McClellan et al.10
described the prevalence of low glomerular filtration rate
(GFR) (defined as GFR estimated by the Modification of Diet
in Renal Disease GFR equation (MDRD GFR) of less than
60 ml/min/1.73 m2) as being 52% in patients surviving
admission for myocardial infarction (MI) and 60% in
survivors of admission for CHF. Over a 3-year follow up,
ESRD occurred in 3% of patients with low GFR and MI, and
in 6.1% of patients with low GFR and CHF. Unless GFR was
low, ESRD was very uncommon in both patients with MI and
CHF (1 of 498 patients). Multivariable analysis of risks for
ESRD was precluded in this data set by the relatively limited
number of patients who developed ESRD (32 events). In this
study, it was not known whether patients had been assessed
by a nephrology sub-specialist either before or after their
index admission.
We primarily studied the rate of ESRD in consecutive
patients discharged after a cardiac event in a large, unbiased
Canadian cohort that receiving universal health coverage. We
secondarily studied the prevalence of renal insufficiency, the
multivariable risk factors for ESRD, the rate of ESRD relative
to the rate of death, the measurement properties of MDRD
GFR, serum creatinine, the measurement properties of
MDRD GFR and serum creatinine in predicting ESRD, the
proportion of patients known by nephrologists before the
admission, and the association of nephrology consultation
with ESRD.
RESULTS
We identified 15,237 unique patients in the database; 9961
had discharge diagnoses of acute coronary syndrome (ACS),
CHF, or both. We excluded patients from the analysis for the
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following reasons: other diagnoses (n¼ 5276), serum
creatinine level absent (n¼ 737), less than 40 mmol/l
(n¼ 19), or greater than 1000 mmol/l (n¼ 7), on renal
replacement therapy prior to admission (n¼ 56), requiring
renal replacement therapy during the index admission
(n¼ 13), died during the index admission (n¼ 887), and/
or unclassifiable with respect to ESRD (n¼ 6). We included
8,236 patients in the final analysis with discharge diagnoses:
ACS (n¼ 4979), CHF (n¼ 2656), and CHF and ACS
(n¼ 601).
Participants excluded on the basis of missing serum
creatinine did not differ by age, sex, diabetes, or discharge
diagnosis from those included (data not shown). Demo-
graphics of the whole study group and the three diagnostic
categories are shown in Table 1.
Over the 4.4- to 7.5-year follow-up period, 113 patients
developed ESRD, a cumulative incidence of 1.4%. Figure 1a
shows that patients with diagnosis of CHF, with or without
ACS, were more likely to develop ESRD than those with
diagnosis of ACS alone (log-rank Po0.0001 and o0.0001,
respectively). Patients with GFR o30 ml/min/1.73 m2 were
more likely to develop ESRD than those with GFR
30–o60 ml/min/1.73 m2 or GFR X60 ml/min/1.73 m2
(Figure 1b) (log-rank Po0.0001 and o0.0001, respectively).
There was no significant difference between patients with
GFR 30–60 ml/min/1.73 m2 and those with GFR X60 ml/
min/1.73 m2 (P¼ 0.0189) using the predetermined Bonfer-
onni-corrected threshold value of 0.006. The cumulative
incidence of ESRD was highest in the subgroup of patients
with GFR o15 ml/min/1.73 m2 (35/110 or 31.8%). Cou-
choud creatinine cut-off points also identified patients likely
to develop ESRD. Patients above the cut-off point corre-
sponding to o30 ml/min/1.73 m2 were more likely to
develop ESRD than those between the 30 and 60 ml/min/
1.73 m2 cut-off points (log-rank Po0.0001) and less likely
than those X60 ml/min/1.73 m2 cut-off point (log-rank
Po0.0001). There was no statistically significant differences
between patients with the 30 and 60 ml/min/1.73 m2 cut-off
points and those with the X60 ml/min/1.73 m2 cut-off point
(log-rank P¼ 0.1149; Figure 1c). Receiver operating char-
acteristic curves showed that serum creatinine level and
MDRD GFR were equally good predictors of ESRD
(Figure 2). Table 2 shows sensitivity, specificity, and like-
lihood ratios for prediction of ESRD.
Table 3 shows the crude hazard rates for mortality and
ESRD. Patients were far more likely to die than to develop
ESRD, except in patients with severely low GFR
(GFRo30 ml/min/1.73 m2).
In the adjusted Cox proportional hazard multivariable
analysis, we found a discharge diagnosis of CHF (alone or
with ACS), moderate and severely low GFR (by MDRD
GFR), diabetes, hypertension, and anemia were independent
Table 1 | Baseline characteristics of study participants
Baseline variables
ACS n=4979 mean
(s.d.) n (%)
CHF n=2656 mean
(s.d.) n (%)
CHF & ACS n=601
mean (s.d.) n (%)
Full cohort n=8236
mean (s.d.) n (%)
Age (years) 65.2 (13.0) 75.8 (11.1) 76.8 (11.4) 69.2 (13.2)
60–o70 years 1270 (25.5%1) 407 (15.3%) 109 (18.1%) 1786 (21.7%)
70–o80 years 1299 (26.1%) 930 (35.0%) 225 (37.4%) 2454 (29.8%)
X80 years 716 (14.4%) 1092 (41.1%) 197 (32.8%) 2005 (24.3%)
Gender (women) 1887 (37.9%) 1415 (53.2%) 291 (48.4%) 3593 (43.6%)
Diabetes 1284 (25.8%) 1050 (39.5%) 293 (48.8%) 2627 (32.9%)
Hypertension 3690 (74.1%) 1822 (68.6%) 447 (74.4%) 5959 (72.4%)
Current smoker 1537 (30.9%) 417 (15.7%) 132 (21.9%) 2086 (25.3%)
Hyperlipidemia 3393 (68.1%) 567 (21.4%) 288 (47.9%) 4248 (51.6%)
GFR (ml/min/1.73 m2) 68.6 (22.6) 53.0 (22.8) 54.2 (22.8) 62.5 (23.9)
Creatinine (mmol/l) 102 (44) 130 (72) 128 (67.6) 113 (58)
GFR
460 ml/min/1.73 m2 3256 (65.4%) 938 (35.3%) 227 (37.8%) 4421 (53.7%)
30–o60 ml/min/1.73 m2 1518 (30.5%) 1288 (48.5%) 279 (46.4%) 3085 (37.5%)
o30 ml/min/1.73 m2 205 (4.1%) 430 (16.2%) 95 (15.8%) 730 (8.9%)
Total cholesterol (mmol/l) 5.2 (1.3) 4.8 (1.4) 4.8 (1.2) 5.2 (1.3)
LDL (mmol/l) 3.2 (1.0) 3.0 (1.1) 3.1 (1.0) 3.2 (1.0)
Hemoglobin (g/l) 139 (17) 127 (21) 130 (21.9) 134 (20)
Hemoglobin
X120 g/l 4396 (88.3%) 1708 (64.3%) 430 (71.6%) 6534 (79.3%)
100–o120 g/l 439 (8.8%) 625 (23.5%) 118 (19.6%) 1182 (14.4%)
o100 g/l 120 (2.4%) 280 (10.5%) 52 (8.7%) 452 (5.5%)
Missing 24 (0.5%) 43 (1.6%) 1 (0.2%) 68 (0.8%)
Previous visit to nephrologist
Total 190 (3.8%) 156 (5.9%) 50 (8.3%) 396 (4.8%)
Pre event 46 (0.9%) 41 (1.5%) 14 (2.3%) 101 (1.2%)
Post event 144 (2.9%) 115 (4.3%) 36 (6.0%) 295 (3.6%)
ACS, acute coronary syndrome; CHF, congestive heart failure; GFR, glomerular filtration rate; LDL, low-density lipoprotein cholesterol.
Missing values: cholesterol, 4,246 (51.6%) and LDL (4,607), 55.9%.
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predictors of the development of ESRD (Table 4). After
adjustment for MDRD GFR, women and older patients were
found to be less likely to develop ESRD than men or younger
patients. After initiation of chronic renal replacement
therapy, mortality was determined to be 80% at 4 years.
Due to statistical concerns of including too many variables
for the number of events, interaction terms for cardiac
diagnosis and GFR levels were not incorporated into the final
multivariate model. Models that included these terms were
terms were run by the author. The results showed that although
hazard ratio for ESRD was higher with decreased GFR, the
magnitude of risk remained higher with CHF diagnosis. This
suggests CHF is an independent predictor of ESRD. Atrial
fibrillation was also not included in the multivariate analysis as
a co-diagnosis due to the small number of patients with atrial
fibrillation who progressed to ESRD (8/113).
We identified, through registry linkage, the following 101
patients who had been assessed by a nephrologist before their
cardiac admission: 84 patients (1.0%) within the previous 2
years and a further 17 patients more than 2 years before. This
included 25 of the 113 (22.1%) who had developed ESRD.
Patients who had been evaluated by a nephrologist, compared
with those who had not, were more likely to have diabetes
(51.5 vs 31.7%; Po0.0001), hypertension (88.1 vs 72.2%;
P¼ 0.0003), decreased renal function (31.7 vs 62.9 ml/min/
1.73 m2; Po0.0001), and lower hemoglobin level (120 vs
136 g/l; Po0.0001), and were less likely to be current smokers
(9.9 vs; 25.5%; P¼ 0.0003). When previous consultation by a
nephrologist was included in the Cox model (Table 4),
nephrology consultation was associated with increased risk of
subsequent ESRD (hazard ratio 4.20; 95% confidence interval
2.49–7.09), and the risks associated with moderate and
severely low GFR were attenuated.
DISCUSSION
This study shows that low GFR is prevalent (46.3%) in
survivors of admission for ACS or CHF. The development of
ESRD (113/8236 or 1.4%) is relatively uncommon at 6 years
ESRD end-stage renal disease; ACS acute coronary syndrome; CHF congestive heart failure 
Log-rank by diagnosis: 
ACS vs ACS & CHF  ≤ 0.0001  
ACS vs CHF                           ≤ 0.0001 
CHF vs ACS & CHF  = 0.4950  
Critical P -value for comparison when adjusting for nine comparisons = 0.05/9= 0.00555 
ACS&CHF  600       460        391       336        295       258        151  
ACS     4979      4697       4490      4303       4145      3968       2777 
CHF     2656      1977       1576      1301       1038    898       586 
GFR glomerular filtration rate; ESRD end-stage renal disease  
Log-rank by GFR class 
< 30 vs ≥ 60 ml/min/1.73 m2 ≤ 0.0001
30 – 60 vs ≥ 60 ml/min/1.73 m2  = 0.0189 
30 – 60 v < 30 ml/min/1.73 m2 ≤ 0.0001  
Critical P -value for comparison when adjusting for nine comparisons = 0.05/9= 0.00555 
GFR < 30     730        432        314        231        167        129        74 
GFR 30- <60 3084       2597       2258       2011       1815       1611      1096 
GFR  ≥ 60    4421       4105       3883       3698       3541       3384      2344 
 
 
ESRD end-stage renal disease; W women; M men 
Log-rank by couchoud cutpoints 
> 146 umol/l (W) or 177 umol/l (M) vs 104 – 146 umol/l (W) or 137 – 177 umol/l (M) ≤ 0.0001 
> 146 umol/l (W) or 177 umol/l (M) vs < 104 umol/l (W) or < 146 umol/l (M) ≤ 0.0001 
104 – 146 umol/l (W) or 137 – 177 umol/l (M) v < 104 umol/l (W) or < 146 umol/l (M) ≤ 0.1149 
Critical P -value for comparison when adjusting for nine comparisons = 0.05/9= 0.00555 
>146(F),>177(M) 5982     5466        5090       4798       4548       4289       2977 
104-146(F), 
137-177(M)      4421     4105        3883       3698       3541       3384       2344 
<104(F),<137(M)  895      562         419        324        248        195        113 
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Figure 1 | End stage renal disease incidence. (a) Kaplan–Meier plot showing cumulative incidence of ESRD by cardiac diagnosis.
(b) Kaplan–Meier plot showing cumulative incidence of ESRD by renal function on admission. (c) Kaplan–Meier plot showing
cumulative incidence of ESRD by creatinine cut-off points.
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of follow-up, except in those patients with GFRo30 ml/min/
1.73 m2 (72/730 (9.9%) when assessed by MDRD GFR,
77/895 (8.6%)) when assessed by Couchoud cut-off points).
At all levels of GFR, these patients are more likely to die than
to develop ESRD. ESRD may have been under-reported,
particularly in the elderly population, due to censoring (patient
or medical decision to pursue conservative management).
We have extended the work of McClellan10 on the risk
of ESRD after cardiac discharge by showing that CHF,
as compared with ACS, is a multivariable risk factor for
ESRD, independent of level of renal function. Rates of
ESRD are lower than those observed by McClellan (0.97%
per annum after MI in McClellan’s data, 0.14% per annum
after ACS in our data; 2.07% after CHF in McClellan’s
data, 0.63 and 0.76% in our data after CHF without and
with ACS, respectively). These differences may be explained
by the selection of the study group (Medicare patients in
McClellan’s study, and the inclusive provincial cohort in
our study), in the health care systems and policies bet-
ween the two countries (US and Canada), and, in the case
of the ischemic group, from the difference in definition
used.
We found that in addition to cardiac discharge diagnosis
and renal function, age, diabetes, hypertension, and
hemoglobin level also predicted ESRD. It is a limitation of
this study that we were unable to include cardiac history and
hyperlipidaemia in the analysis because of the large number
of missing values for these data items (64 and 54.1%
respectively). After adjustment for level of renal function, we
found that older patients were less likely to reach ESRD than
younger patients, consistent with effects identified in
unselected outpatients by others.11,12 It is likely that the
lower ESRD risk in the elderly reflects informative censoring
and increased competing risks of death in elderly people. It is
also possible that low GFR may not carry the same prognostic
value in elderly people as in young people: low GFR in
younger people may reflect pathologic processes with a
MDRD GFR 
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Figure 2 | Receiver operating characteristic curves showing
measurement properties of MDRD GFR and of serum
creatinine at admission as predictors of ESRD within 4.44
years. Measurement properties of age and urea are shown only
in a tabulated format.
Table 2 | Sensitivity, specificity, positive, and negative likelihood ratios for o60 and o30 ml/min/1.73 m2 thresholds for
Couchoud cut-off points and MDRD GFR–sensitivity/specificity of model with a 4.44-year ESRD event cut-off
ESRD Test characteristics of cut point
Test Yes No Sensitivity (95% CI) Specificity (95% CI) LR +ve LR ve
Using Couchoud cut-off points
o60 ml/min/1.73 m2a
Yes 81 2172 85.3 (76.8, 91.0) 73.3 (72.3, 74.3) 3.2 (2.9, 3.5) 0.2 (0.1, 0.3)
No 14 5969
o30 ml/min/1.73 m2
b
Yes 74 821 77.9 (68.6, 85.1) 89.9 (89.2, 90.6) 7.7 (6.8, 8.8) 0.2 (0.2, 0.4)
No 21 7320
Using MDRD GFR
o60 ml/min/1.73 m2
Yes 85 3730 89.5 (81.7, 94.2) 54.2 (53.1, 55.3) 2.0 (1.8, 2.1) 0.2 (0.1, 0.3)
No 10 4411
o30 ml/min/1.73 m2
Yes 70 660 73.7 (64.0, 73.5) 91.9 (91.3, 92.5) 9.1 (7.9, 10.5) 0.3 (0.2, 0.4)
No 25 7481
Overall 95 8141
CI, confidence interval; ESRD, end-stage renal disease (at 4.44-year follow-up); LR ve, likelihood ratio if negative; LR +ve, likelihood ratio if positive; MDRD GFR, glomerular
filtration rate estimated according to the Modification of Diet in Renal Disease equation.
aSerum creatinine: 4146 mmol/l (women) or 4177 mmol/l (men).
bSerum creatinine: X104 mmol/l (women) or X137 mmol/l (men).
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higher likelihood of progression, whereas in many elderly
people low GFR may simply reflect age-related decline.
Diabetes and hypertension are both well-described risk
factors for progression of kidney disease.13,14 Anemia, although
a risk factor, may not be a causal link for ESRD development,
but is more likely associated with other risk factors for
progression such as inflammation, comorbidity, or more
advanced renal insufficiency within the GFR class.
A recent meta-analysis found no evidence that improving the
hemoglobin status with erythropoietin reduced progression of
renal failure.15
One of the current areas of discussion within nephrology
community is how to define and communicate CRI to the
non-nephrology community.16 Consensus guidelines argue
that reporting serum creatinine be abandoned in favor of an
estimation of GFR based on an accepted formula.17 Our
present analysis shows that Couchoud sex-specific cut-off
points of creatinine greater than 146 mmol/l for women or
177 mmol/l (equivalent to a GFR ofo30 ml/min/1.73 m2) are
as valid as cut-off points defined by MDRD GFR in defining
high risk for progression to ESRD in this patient group. In
receiver operating characteristic curves curve analysis, sex-
specific serum creatinine performs as well as a predictor of
ESRD before death as does MDRD GFR.
Recent studies of elderly patients with diabetes in the
general population have compared the risks of death and
ESRD stratified by baseline GFR.11,18–21 These studies showed
the risk of death to be greater than the requirement for renal
replacement therapy, even for people with low GFR. Keith
et al.19, studying a managed care organization, showed
mortality/ESRD rate ratios of 17.7, 18.7, and 2.3 for
GFRX60, 30–o60, and o30 ml/min/1.73 m2, respectively.
Go et al.20 studied the members of a similar registry and
found high mortality, but low progression of 0.28%, to
dialysis treatment and 0.03% to transplant. These rates are
Table 3 | Crude mortality rates and rates of ESRD, stratified by
cardiac diagnosis, age and renal function
Death/100 patient
years
ESRD/100
patient years Death/ESRD
Full cohort 9.34 (8.85, 9.82) 0.29 (0.20, 0.38) 31.99
Cardiac diagnosis
ACS 4.69 (4.39, 4.99) 0.14 (0.091, 0.20) 32.48
CHF 21.80 (21.00, 22.60) 0.64 (0.48, 0.79) 34.27
CHF and ACS 17.31 (15.76, 18.85) 0.77 (0.41, 1.13) 22.45
Age (years)
o60 2.11 (1.78, 2.43) 0.27 (0.15, 0.39) 7.80
60–69 5.88 (5.32, 6.44) 0.32 (0.18, 0.45) 18.51
70–79 11.91 (11.25, 12.56) 0.34 (0.22, 0.46) 34.80
X80 23.10 (22.16, 24.04) 0.21 (0.11, 0.32) 108.72
GFR (ml/min/1.73 m2)
460 5.37 (5.04, 5.71) 0.08 (0.037, 0.12) 67.38
30–o60 13.10 (12.50, 13.71) 0.17 (0.093, 0.24) 78.62
o30 33.45 (31.70, 35.19) 4.27 (3.52, 5.02) 7.83
ACS, acute coronary syndrome; CHF, congestive heart failure; ESRD, end-stage renal
disease; GFR, glomerular filtration rate.
Table 4 | Cox proportional hazards model for ESRD, estimating glomerular filtration rate with MDRD GFR, and with Couchoud’s
cut-off points
Models using MDRD GFR to estimate GFR
category
Models using Couchoud cut-off points to estimate GFR
category
Variable Hazard ratio 95% CI Hazard ratio 95% CI Hazard ratio 95% CI Hazard ratio 95% CI
Cardiac diagnosis
ACS Referent Referent Referent Referent
CHF 1.79 (1.13, 2.82) 1.91 (1.21, 3.02) 1.84 (1.16, 2.90) 1.97 (1.25, 3.12)
CHF and ACS 2.35 (1.30, 4.25) 2.04 (1.12, 3.69) 2.23 (1.22, 4.06) 2.00 (1.10, 3.62)
GFR (ml/min/1.73 m2)
460 Referent Referent Referent Referent
30–o60 2.37 (1.24, 4.50) 1.99 (1.04, 3.79) 1.91 (0.88, 4.156) 1.54 (0.70, 3.36)
o30 35.9 (19.7, 65.6) 25.4 (13.7, 47.3) 23.29 (13.92,38.96)) 17.45 (10.28,29.63)
Diabetes 2.87 (1.87, 4.40) 2.78 (1.81, 4.27) 2.69 (1.75, 4.12) 2.58 (1.68, 3.96)
Age (years)
o60 Referent Referent Referent Referent
60–69 0.66 (0.39, 1.12) 0.97 (0.57, 1.67) 0.67 (0.40, 1.13) 1.01 (0.59, 1.72)
70–79 0.44 (0.26, 0.75) 0.68 (0.40, 1.18) 0.41 (0.24, 0.68) 0.66 (0.38, 1.13)
X80 0.18 (0.09, 0.36) 0.28 (0.14, 0.57) 0.18 (0.09, 0.35) 0.28 (0.14, 0.57)
Women 0.64 (0.45, 0.95) 0.69 (0.46, 1.0) 0.74 (0.51, 1.10) 0.78 (0.53, 1.16)
Hypertension 3.02 (1.56, 5.82) 2.71 (1.40, 5.24) 2.93 (1.52, 5.64) 2.60 (1.34, 5.03)
Smoker current 1.46 (0.92, 2.34) 1.74 (1.10, 2.78) 1.36 (0.86, 2.17) 1.66 (1.05,2.64)
Hemoglobin
4120 g/l Referent Referent Referent Referent
100–o120 g/l 1.75 (1.06, 2.88) 1.61 (0.98, 2.64) 1.91 (1.16, 3.13) 1.70 (1.04, 2.78)
o100 g/l 3.95 (2.37, 6.60) 4.00 (2.39, 6.67) 4.50 (2.71, 7.48) 4.40 (2.64, 7.33)
Nephrology visit pre admission Not included 4.20 (2.49, 7.09) Not included 4.95 (2.95, 8.29)
ACS, acute coronary syndrome; CHF, congestive heart failure; ESRD, end-stage renal disease; MDRD GFR glomerular filtration rate estimated using the modification of diet in
renal disease equation.
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lower than that in our participants (Table 3), who were at
higher mortality risk on account of their recent hospitaliza-
tion for a cardiac event. Similarly, two large population-based
studies have shown a higher rate of development of vascular
disease and death rather than ESRD.21,22
Several groups have conducted post hoc analysis of the
antihypertensive and lipid lowering treatment to prevent heart
attack trial and showed high rates of cardiovascular events and
low rates of ESRD.23–25 The impact of death was under-
estimated in our study, as death in hospital was excluded. A
re-analysis of our data with the inception time point at the
day of admission rather than discharge, shows relative rates of
death to ESRD of 96, 92, and 10 for GFRX60, GFR 30–o60,
and o30 ml/min/1.73 m2, respectively.
We found that very few patients, 2.4% of those with low
GFR and 7.7% of those with GFR less than 30 ml/min/
1.73 m2, had been assessed by a nephrologist before cardiac
admission. Patel et al.18 similarly reported a low rate of
assessment of patients with severe CRI by nephrology sub-
specialists in a cohort of elderly patients. Our data, however,
suggest that the use of nephrology consultation may have
been carefully selective: the finding of a positive association
between nephrology visit and ESRD is likely due to the
referral of those with more progressive disease. This
hypothesis is supported by the finding of higher prevalence
of the risk markers diabetes and hypertension, and by the
lower GFRs and lower hemoglobin levels observed in those
referred compared with those who were not (The alternative
hypothesis that nephrology referral is harmful cannot be
excluded, but seems unlikely).
We have shown that patients discharged from hospital
following cardiac events, who have low GFR, are at high risk
of death, and that this increases in a stepwise manner at lower
levels of GFR. However, in univariate analysis, we were unable
to show a difference between patients with GFR 30–o60 ml/
min/1.73 m2 and those with GFR X60 ml/min/1.73 m2 with
respect to risk of progression to ESRD. In multivariable
analysis, the hazard ratio for ESRD in patients with MDRD
GFR 30–o60 ml/min/1.73 m2 is 2.37 (95% confidence interval
1.24–4.50), compared with 35.9 (95% confidence interval
19.7–65.6) for those with GFRo30 ml/min/1.73 m2. These
results are congruent with those of Hallan et al.21 who
followed 65,604 participants in a population-based health
survey in Nord-Tondelag County, Norway, and found that
although 20% of those with GFR less than 30 ml/min/1.73 m2
progressed to ESRD over the subsequent 8 years, ESRD
occurred in only 2 and 1% of those with GFR 30–45 and
45–60 ml/min/1.73 m2, respectively.
In our participants with GFR 30–o60 ml/min/1.73 m2,
death was 79 times more likely than ESRD. The lower rates of
ESRD are likely the result of competing risk of death. Since
no specific nephrologic interventions have been shown to
decrease the risk of death, our data support selective, rather
than universal, nephrology consultation for people with GFR
in this range. Their optimal investigation and management
warrants further research. Given that these patients have had
a cardiovascular event, they are at increased risk of
subsequent events and mortality. They should receive
maximal cardiovascular risk reduction therapy regardless of
CRI status.26–28 We have previously reported that therapy is
often less intense post cardiac event in those with CRI.4
Patients discharged following a cardiac event, whose GFR
is o30 ml/min/1.73 m2, experience a different prognosis:
33.5% annual mortality, 4.3% annual risk of ESRD, and a
much lower ratio of death to ESRD of 7.8. Similarly, in the
general population, using more extreme cut-off points for
creatinine of 4300 mmol/l in men and 4250 mmol/l in
women, Evans et al.12 identified a group with 80%
progression to ESRD over 6 years. The likelihood that these
patients will benefit from the scarce resource of nephrology
consultation is much higher.
Our study has several limitations. This was an observa-
tional study; while the findings may indicate associations,
they cannot establish causal relationships. We assigned a renal
function group based on a single serum creatinine level on
admission without knowledge of prior or follow-up values.
Patients who left the province or had events out of province
may not have been included; therefore, this analysis may have
underestimated actual events.
We may have underestimated the proportion of patients
assessed by nephrology sub-specialists: some patients could
have been seen earlier than our linkage date, and some may
have been seen by internists with expertise in nephrology who
work in rural communities. We do not know the reasons for
referral and risk factors at the time of referral. We did not have
information on proteinuria and the rate of change of GFR,
both of which are likely to be important predictors of ESRD.
In summary, clinically important risk factors for deve-
lopment of ESRD in patients admitted for a cardiac event are
easily identifiable. Rates of progression to ESRD in people
with GFR 30–o60 ml/min/1.73 m2 in the medium term are
low. High competing risks of death likely contribute to the
observed, relatively low rates of ESRD.
MATERIALS AND METHODS
We used the Improving Cardiovascular Outcomes in Nova
Scotia (ICONS) database that was introduced in October
1997 to study health outcomes, interventions, and resource
utilization of consecutive adult (X18 years) patients
admitted to hospitals in Nova Scotia, Canada. The ICONS
database includes information on patients admitted with a
diagnosis of ACS (defined as MI or unstable angina), CHF, or
atrial fibrillation. It is a prospective, province-wide, popula-
tion-based, cohort study of consenting adults. The Capital
District Health Authority Research Ethics Board approved
the study protocol. Further details of the ICONS study design
and methodology have been published.29
Inclusion criteria
The study patients were admitted to hospital between
1 October 1997 and 31 October 1999, survived to discharge,
and had a discharge diagnosis of ACS or CHF. Each patient
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record was unique, and for patients with multiple
admissions, the first admission during the time period was
used.
Exclusion criteria
Patients discharged with a diagnosis other than ACS or CHF
were excluded from the analysis. We did not include the
population with atrial fibrillation alone as an independent
group, but are looking at that presently. Patients with serum
creatinine value missing; less than 40 mmol/l; or greater than
1000 mmol/l; patients with ESRD (defined below) before
admission; or who reached ESRD during the index admission
were also excluded.
Definitions
We classified patients by discharge diagnosis into the
following three mutually exclusive groups: ACS, CHF,
or ACS and CHF. We used the MDRD modified formula,
based on the admission creatinine, to estimate the GFR in
ml/min/1.73 m2.30 The coefficient for the Black race was
not included in the formula, as race was not documented
in the records (The Nova Scotia population is overwhel-
mingly Caucasian: in the 2001 provincial census, only 1.5%
of the population identified themselves as Black or of African
origin). We classified renal function into three groups:
GFR X60 ml/min/1.73 m2, GFR 30–o60 ml/min/1.73 m2,
and GFRo30 ml/min/1.73 m2. We classified hemoglobin
into three groups: X120, 100–o120, and o100 g/l. We used
the diagnosis coded at discharge by medical records
personnel (according to the International Classification of
Disease, Ninth Revision, Clinical Modification Codes)
restricted to 398.9, 410–414, 427.3, 428, 786, and 786.5.
We determined the incidence of ESRD by linkage
of the ICONS database to the provincial Nova Scotia
Department of Heath Medical Service Insurance registry
to 31 March 2005, which permitted identification of
physician billing codes for transplantation or dialysis.
In Nova Scotia, all physician’s fees for these services are
submitted to the province and recorded in this database. We
defined ESRD as treatment with transplantation, peritoneal
dialysis, or with treatment by hemodialysis for more than 13
treatments and more than 30 days (Acute peritoneal dialysis
is not practiced in Nova Scotia). People who were on
hemodialysis for fewer than 30 days at death, or whose
death was less than 2 weeks after the last dialysis, were also
considered to have ESRD. Patients who were on hemodialysis
for fewer than 13 treatments or for fewer than 30 days at
the end of the study follow-up period were considered
unclassifiable. For patients defined as having ESRD, the date
of ESRD was the date of the first dialysis treatment or
transplant.
Laboratory testing
We used the admission laboratory data analyzed at the
admitting hospitals. No calibration of laboratory creatinine
measurement was performed.
Data collection
Trained nurses and health records professionals abstracted
baseline variables, laboratory investigations, and discharge
medication from the hospital charts. The data were
entered into a central ICONS registry database. Patient
baseline variables included were age, gender, hypertension
(defined as admission blood pressure X140 mm Hg systolic
or X90 mm Hg diastolic or a history of hypertension),
smoking (current), hyperlipidaemia (defined as total
cholesterol 46.2 mmol/l or low-density lipoprotein choles-
terol 42.6 mmol/l, or a history of hyperlipidaemia), and
diabetes (defined as random blood glucose 411.1 mmol/l or
a history of diabetes).
Primary outcome
We determined the primary outcome, ESRD, by linkage of
the ICONS database to the provincial Medical Service
Insurance registry from 1 October 1995 to 31 March 2005.
Secondary outcomes
We determined mortality by linkage of the ICONS database
to the provincial vital statistics registry from 1 October 1997
to 31 March 2005. We determined referral to a nephrologist
by linkage of ICONS database with the provincial Medical
Service Insurance registry from 1 October 1995 to 31 March
2005 (In Nova Scotia, all visits to a nephrologist result in a
physician fee claim being submitted to the provincial
government and recorded in this database).
Statistics
We reported baseline patient characteristics as percentages
and means (with s.d.) for the three discharge diagnoses
groups. We studied the primary ESRD outcome by death-
censored unadjusted Kaplan–Meier analysis stratified by
discharge diagnoses (a), renal function classified by the
MDRD GFR (b), and renal function based on Couchoud
creatinine cut-off points of 60 ml/min/1.73 m2 (104 mmol/l
for women and 137 mmol/l for men), and of 30 ml/min/
1.73 m2 (146 mmol/l for women and 177 mmol/l for men) (c).
We compared differences between groups (based on dis-
charge diagnosis, GFR class by MDRD GFR, and Couchoud’s
cut-off points) by log-rank analysis with a value of 0.006
considered significant, based on Bonferonni statistical
adjustment of the desired alpha level of 0.05 for nine
comparisons.31
We used Cox proportional hazards regression modeling to
examine the effect of cardiac diagnosis and renal function on
the risk of ESRD. Other variables included in the model were
age, gender, traditional risk factors (diabetes, hypertension
and current smoking), and hemoglobin level. We forced all
these variables in the model, regardless of effect size or
statistical significance, because of the known prognostic
importance of each. We constructed models with and
without the variable pre-admission nephrology consultation.
We estimated crude hazard rates for death and ESRD using a
Poisson distribution. For construction of receiver operating
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characteristic curves and for estimation of sensitivity and
specificity, in order to avoid problems created by censored
observations, we dichotomized patient data into ESRD or no
ESRD at 4.44 years (the shortest observed follow-up time).
We considered a two-sided P-value of less than 0.05 as
statistically significant. We performed analyses with SAS V9.1
(SAS Institute, Cary, NC, USA) and SPSS 11.0 (SPSS Inc.,
Chicago, IL, USA).
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